vs
RHYTHM PHARMACEUTICALS, INC.（RYTM）与STEM, INC.（STEM）财务数据对比。点击上方公司名可切换其他公司
RHYTHM PHARMACEUTICALS, INC.的季度营收约是STEM, INC.的1.2倍（$57.3M vs $47.1M），STEM, INC.净利率更高（-33.9% vs -83.0%，领先49.1%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（36.9% vs -15.6%），过去两年RHYTHM PHARMACEUTICALS, INC.的营收复合增速更高（48.5% vs 36.1%）
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
该公司是一家公开上市的生物制药企业，总部位于加利福尼亚州纽瓦克，专注研发纯化人类神经干细胞，旨在治疗中枢神经系统疾病与瘫痪，其所研发的神经干细胞可分化为中枢神经系统的神经元、星形胶质细胞与少突胶质细胞这三大主要细胞类型。
RYTM vs STEM — 直观对比
营收规模更大
RYTM
是对方的1.2倍
$47.1M
营收增速更快
RYTM
高出52.4%
-15.6%
净利率更高
STEM
高出49.1%
-83.0%
两年增速更快
RYTM
近两年复合增速
36.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.3M | $47.1M |
| 净利润 | $-47.5M | $-16.0M |
| 毛利率 | 91.6% | 48.9% |
| 营业利润率 | -82.2% | -17.7% |
| 净利率 | -83.0% | -33.9% |
| 营收同比 | 36.9% | -15.6% |
| 净利润同比 | -9.6% | 68.8% |
| 每股收益（稀释后） | $-0.73 | $-4.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RYTMSTEM
| Q4 25 | $57.3M | $47.1M | ||
| Q3 25 | $51.3M | $38.2M | ||
| Q2 25 | $48.5M | $38.4M | ||
| Q1 25 | $32.7M | $32.5M | ||
| Q4 24 | $41.8M | $55.8M | ||
| Q3 24 | $33.3M | $29.3M | ||
| Q2 24 | $29.1M | $34.0M | ||
| Q1 24 | $26.0M | $25.5M |
净利润RYTMSTEM
| Q4 25 | $-47.5M | $-16.0M | ||
| Q3 25 | $-52.9M | $-23.8M | ||
| Q2 25 | $-46.6M | $202.5M | ||
| Q1 25 | $-49.5M | $-25.0M | ||
| Q4 24 | $-43.3M | $-51.1M | ||
| Q3 24 | $-43.6M | $-148.3M | ||
| Q2 24 | $-32.3M | $-582.3M | ||
| Q1 24 | $-141.4M | $-72.3M |
毛利率RYTMSTEM
| Q4 25 | 91.6% | 48.9% | ||
| Q3 25 | 89.3% | 35.5% | ||
| Q2 25 | 88.6% | 33.4% | ||
| Q1 25 | 88.8% | 32.4% | ||
| Q4 24 | 90.9% | -4.4% | ||
| Q3 24 | 88.5% | 21.2% | ||
| Q2 24 | 89.9% | 27.6% | ||
| Q1 24 | 89.2% | -95.0% |
营业利润率RYTMSTEM
| Q4 25 | -82.2% | -17.7% | ||
| Q3 25 | -102.6% | -33.6% | ||
| Q2 25 | -93.4% | -34.8% | ||
| Q1 25 | -143.7% | -65.0% | ||
| Q4 24 | -98.6% | -84.4% | ||
| Q3 24 | -132.0% | -493.2% | ||
| Q2 24 | -139.2% | -1705.5% | ||
| Q1 24 | -538.7% | -267.0% |
净利率RYTMSTEM
| Q4 25 | -83.0% | -33.9% | ||
| Q3 25 | -103.1% | -62.2% | ||
| Q2 25 | -96.1% | 527.8% | ||
| Q1 25 | -151.4% | -76.9% | ||
| Q4 24 | -103.6% | -91.6% | ||
| Q3 24 | -131.2% | -506.3% | ||
| Q2 24 | -110.9% | -1712.6% | ||
| Q1 24 | -544.4% | -283.9% |
每股收益（稀释后）RYTMSTEM
| Q4 25 | $-0.73 | $-4.40 | ||
| Q3 25 | $-0.82 | $-2.84 | ||
| Q2 25 | $-0.75 | $-1.79 | ||
| Q1 25 | $-0.81 | $-0.15 | ||
| Q4 24 | $-0.71 | $-15.29 | ||
| Q3 24 | $-0.73 | $-18.24 | ||
| Q2 24 | $-0.55 | $-71.81 | ||
| Q1 24 | $-2.35 | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.9M | $48.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $139.1M | $-249.4M |
| 总资产 | $480.2M | $308.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RYTMSTEM
| Q4 25 | $388.9M | $48.9M | ||
| Q3 25 | $416.1M | $43.1M | ||
| Q2 25 | $291.0M | $40.8M | ||
| Q1 25 | $314.5M | $58.6M | ||
| Q4 24 | $320.6M | $56.3M | ||
| Q3 24 | $298.4M | $75.4M | ||
| Q2 24 | $319.1M | $89.6M | ||
| Q1 24 | $201.2M | $112.8M |
股东权益RYTMSTEM
| Q4 25 | $139.1M | $-249.4M | ||
| Q3 25 | $148.8M | $-235.7M | ||
| Q2 25 | $-11.9M | $-214.1M | ||
| Q1 25 | $18.9M | $-417.5M | ||
| Q4 24 | $21.7M | $-398.4M | ||
| Q3 24 | $11.2M | $-344.1M | ||
| Q2 24 | $39.3M | $-203.2M | ||
| Q1 24 | $61.6M | $371.6M |
总资产RYTMSTEM
| Q4 25 | $480.2M | $308.9M | ||
| Q3 25 | $506.9M | $362.6M | ||
| Q2 25 | $372.7M | $379.2M | ||
| Q1 25 | $386.7M | $405.1M | ||
| Q4 24 | $392.3M | $437.4M | ||
| Q3 24 | $363.6M | $537.8M | ||
| Q2 24 | $381.8M | $691.5M | ||
| Q1 24 | $258.7M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-25.4M | $8.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流RYTMSTEM
| Q4 25 | $-25.4M | $8.2M | ||
| Q3 25 | $-26.6M | $11.4M | ||
| Q2 25 | $-23.3M | $-21.3M | ||
| Q1 25 | $-40.4M | $8.5M | ||
| Q4 24 | $-18.8M | $-14.7M | ||
| Q3 24 | $-25.2M | $-9.4M | ||
| Q2 24 | $-29.1M | $-11.9M | ||
| Q1 24 | $-40.7M | $-621.0K |
现金转化率RYTMSTEM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
